CLINICAL TRIALS PROFILE FOR AMPRELOXETINE
✉ Email this page to a colleague
Clinical Trials for ampreloxetine
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT03750552 ↗ | Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure | Completed | Theravance Biopharma | Phase 3 | A Phase 3 study to evaluate efficacy, safety, and tolerability of ampreloxetine (TD-9855) in subjects with primary autonomic failures (MSA, PD, or PAF) and symptomatic nOH with up to 4 weeks of treatment. |
NCT03829657 ↗ | Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure | Active, not recruiting | Theravance Biopharma | Phase 3 | A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of ampreloxetine in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure |
NCT04095793 ↗ | Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure | Active, not recruiting | Theravance Biopharma | Phase 3 | A Phase 3, multi-center, open-label study to evaluate the safety and tolerability of ampreloxetine in subjects with primary autonomic failures (MSA, PD, and PAF) and symptomatic nOH over 182 weeks. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for ampreloxetine
Condition Name
Clinical Trial Locations for ampreloxetine
Trials by Country
Clinical Trial Progress for ampreloxetine
Clinical Trial Phase
Clinical Trial Sponsors for ampreloxetine
Sponsor Name